Clinical trial
Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in…
NCT00201695 · Ohio State University Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00201695 |
|---|---|
| Title | Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma |
| Official title | Phase II Trial of Pegylated Liposomal Doxorubicin (Doxil), Vincristine, and Dexamethasone (DVd) in Combination With Arsenic Trioxide (Trisenox) in Untreated Patients With Symptomatic Multiple Myeloma |
| Lead sponsor | Ohio State University Comprehensive Cancer Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Doxil®, Vincristine, Dexamethasone, Arsenic Trioxide |
| Enrollment | 12 |
| Start date | Jul 1, 2004 |
| Primary completion | Sep 1, 2006 |
| Completion | Aug 1, 2008 |
| First posted | Sep 20, 2005 |
| Last update posted | Jun 10, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: